Recombinant Human Anti-CD19 x Human Anti-CD3 Bispecific Antibody (scIgG) (SCIGG-H218)

Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD19 and anti-CD3 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

CD19 & CD3

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Follicular lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD19 x Human Anti-CD3 Bispecific Antibody (scIgG) (SCIGG-H218). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD19 x Human Anti-CD3 Bispecific Antibody (scIgG) (CAT#: SCIGG-H218)

Specifications

Targets

Customer Reviews and Q&As